The High Cost of Trial and Error
The pharmaceutical industry faces a sobering reality: only about 8% of drug candidates that enter clinical trials ever receive regulatory approval. This 92% failure rate represents not just a massive financial sinkhole, but years of wasted research and delayed patient access to life-saving treatments. The core of the problem often lies in the reliance on animal-derived models or 2D cultures that fail to replicate complex human biology.
A Shift Toward Human-Relevant Models
VivoSim Labs (NASDAQ: VIVS) is attempting to bridge this gap with its proprietary NAMkind™ technology. By developing 3D human liver and intestinal models, the company aims to provide more accurate safety insights than traditional testing methods. These models act as a filter, allowing pharmaceutical developers to identify toxicity signals early in the R&D process—before significant capital is committed to large-scale human clinical trials.
- NAMkind™ 3D models specifically target human-relevant liver and intestinal tissue.
- AI-powered predictive toxicology provides rapid analysis to identify drug liabilities.
- Early screening capabilities designed to operate during hit-to-lead and lead optimization phases.
- Reduction in dependency on misleading 2D or animal-derived testing models.
The Impact on Drug Development Economics
The economic implications of this approach are significant. By flagging unsuccessful candidates earlier, VivoSim Labs hopes to help companies discontinue dead-end projects sooner or pivot their chemistry toward safer alternatives. This strategy is centered on three decision-critical points: prospective screens, biomarker identification, and guiding the selection of predictive in vivo animal models.
VivoSim Labs is targeting one of pharmaceutical development's most expensive challenges: identifying drug toxicity before a candidate reaches human clinical trials.
— Corporate Statement, September 2026